Retifanlimab
Zynyz (retifanlimab) is an antibody pharmaceutical. Retifanlimab was first approved as Zynyz on 2023-03-22. It is used to treat merkel cell carcinoma in the USA. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
Trade Name
FDA
EMA
Zynyz
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zynyz | Biologic Licensing Application | 2025-05-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| merkel cell carcinoma | EFO_1001471 | D015266 | C4A |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
retifanlimab, Zynyz, Incyte Corporation | |||
| 2030-03-22 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 13 | 5 | 1 | — | — | 16 |
| Carcinoma | D002277 | — | C80.0 | 2 | 11 | 1 | — | 1 | 14 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 6 | 2 | — | 1 | 10 |
| Non-small-cell lung carcinoma | D002289 | — | — | 6 | 3 | 2 | — | — | 9 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 5 | 1 | — | — | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 4 | 1 | — | — | 5 |
| Head and neck neoplasms | D006258 | — | — | 2 | 3 | 1 | — | — | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | 2 | — | — | 3 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | 1 | — | — | 2 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 3 | — | — | — | 5 |
| Colorectal neoplasms | D015179 | — | — | 5 | 2 | — | — | — | 5 |
| Melanoma | D008545 | — | — | 3 | 3 | — | — | — | 4 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 3 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 4 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 1 | 4 | — | — | — | 4 |
| Glioma | D005910 | EFO_0000520 | — | — | 2 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | 1 | 2 | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 2 | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 1 | — | — | — | 2 |
Show 25 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic ductal carcinoma | D021441 | — | — | 2 | — | — | — | — | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
| Malignant mesothelioma | D000086002 | — | — | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Gastrointestinal diseases | D005767 | — | — | 1 | — | — | — | — | 1 |
| Hereditary sensory and autonomic neuropathies | D009477 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Retifanlimab |
| INN | retifanlimab |
| Description | Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2079108-44-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298037 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15766 |
| UNII ID | 2Y3T5IF01Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zynyz – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 627 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
112 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use